Tracking Cathie Wood: Betting on AI healthcare CRSP, continuing to sell medical hardware tool LAB

On Tuesday Eastern Time, the three major indexes ended mixed. The S&P 500 Index closed slightly lower in volatile trading, the Dow fell 0.07%, and the Nasdaq rose 0.01%. As oil prices retreated, traders continued to monitor the situation of the Iran war.

Through the latest trading data on March 10, we can clearly see that ARK is continuing to implement its "weeding out the weak and keeping the strong" and "cross-cycle positioning" trading philosophy. On this day, Cathie Wood executed a textbook-level "underlying asset reallocation" in the healthcare sector: completely abandoning traditional medical hardware and tools, and placing big bets on gene-editing technology with disruptive potential; meanwhile, forward-looking fine-tuning was also carried out in the tech and crypto-asset sectors.

Buying direction: Betting on AI healthcare and emerging infrastructure within the crypto ecosystem.

Cathie Wood made a significant purchase/addition of a gene-editing leader in a single day. $CRISPR Therapeutics (CRSP.US)$ Up to 280,600 shares, this is an aggressive move by ARK in the healthcare sector. CRISPR, as a pioneer in gene-scissors technology, represents a leap from traditional "laboratory trial-and-error" to "precise rewriting of underlying genes" in pharmaceutical R&D. While continuously divesting from traditional medical hardware, Cathie Wood concentrated her firepower on CRSP, aiming to capture the non-linear growth dividends brought about by humanity's breakthroughs in tackling rare and genetic diseases.

In addition, she bought into the Solana staking ETF. $3iQ Solana Staking ETF (SOLQ.CA)$ 25,000 shares. ARK’s layout in crypto-assets has long expanded from a single focus on Bitcoin to encompass the entire Web3 infrastructure. With its extremely high throughput and very low transaction fees, Solana is becoming the core underlying network for decentralized finance (DeFi) and high-frequency on-chain applications. The purchase of SOLQ reflects ARK’s high-probability bet on the next-generation high-performance Layer-1 public blockchain ecosystem.

Additionally, she increased her position in genomics diagnostics companies. $GeneDx Holdings (WGS.US)$ 6,828 shares. This reflects ARK’s refined management strategy in maintaining exposure to specific high-barrier gene data and precision diagnostics.

Selling direction: Reducing positions in medical hardware tools and semiconductor equipment.

Cathie Wood continued to sell off life science tool companies. $Standard BioTools (LAB.US)$ As much as 136,200 shares were slashed from a giant in single-cell sequencing, $10x Genomics (TXG.US)$ while 72,400 shares were involved. Combined with the purchase of CRSP, this set of actions formed a perfect closed loop. In the absence of foundational large models and data ecosystem empowerment, the growth ceiling for pure standalone medical testing hardware and sequencing instruments has become apparent, making it extremely easy to fall into a price war in a highly competitive market. Capital is rapidly flowing from these 'tool providers' to the application side that controls core underlying therapies.

There was also a reduction in shares of an automation testing equipment and collaborative robotics company, $Teradyne (TER.US)$ with 21,500 shares reduced. Teradyne's business spans semiconductor testing and robotics. ARK chose to reduce its stake at this moment as a natural response to the shift of industry value chains towards higher added-value sectors.

Futubull's [Opportunities Page] has launched a feature to track celebrity portfolio opportunities! Choose from multiple celebrity portfolios, one-click follow the moves of top investors, precisely lock in high-quality stocks, and invest with greater confidence!

115K Views